You can buy or sell Neurotrope and other stocks, options, ETFs, and crypto commission-free!
Neurotrope, Inc. Common Stock, also called Neurotrope, is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. Read More The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
PR NewswireMar 11
Neurotrope Reports Year End 2018 Financial Results
NEW YORK, March 11, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), provided financial results for the year ended December 31, 2018. As of December 31, 2018, the Company had approximately $28.8 million of cash and cash equivalents. The Company raised approximately $20.5 million of net cash proceeds in December 2018. With these funds and its cash on hand, the Compa...